protocolSection identificationModule nctId: NCT06361238, orgStudyIdInfo id: 2023-LCYJ-PY-21, briefTitle: Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, class: OTHER, descriptionModule briefSummary: This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery., conditionsModule conditions: Delirium, Postoperative, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 260, type: ESTIMATED, armsInterventionsModule interventions name: Liraglutide injection, interventions name: Placebo injection, outcomesModule primaryOutcomes measure: The incidence of delirium, secondaryOutcomes measure: The severity of delirium, secondaryOutcomes measure: Cognitive function, secondaryOutcomes measure: Anxiety, secondaryOutcomes measure: Depression, secondaryOutcomes measure: Duration of ICU stay, secondaryOutcomes measure: Mechanical ventilation time, secondaryOutcomes measure: Duration of hospital stay, secondaryOutcomes measure: In-hospital mortality, secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Rate of major cardiovascular adverse events, secondaryOutcomes measure: Serum levels of NSE, secondaryOutcomes measure: Serum levels of CRP, secondaryOutcomes measure: Serum levels of IL-1α, secondaryOutcomes measure: Serum levels of TNF-α, secondaryOutcomes measure: Serum levels of C3, secondaryOutcomes measure: Serum levels of LDH, secondaryOutcomes measure: Serum levels of CK, secondaryOutcomes measure: Serum levels of CK-MB, secondaryOutcomes measure: Serum levels of AST, secondaryOutcomes measure: Serum levels of cTNT, secondaryOutcomes measure: Serum levels of BNP, secondaryOutcomes measure: Serum levels of C1q, secondaryOutcomes measure: Serum levels of IL-1β, secondaryOutcomes measure: Serum levels of IL-6, secondaryOutcomes measure: Serum levels of S100β, secondaryOutcomes measure: Left Ventricular Posterior Wall Thickness in Diastole (LVPWTd), secondaryOutcomes measure: Left Ventricular End-Diastolic Dimension (LVDd), secondaryOutcomes measure: Left Ventricular End-Systolic Diameter (LVDs), secondaryOutcomes measure: Left Atrial Diameter (LAD), secondaryOutcomes measure: Ejection Fraction (EF), secondaryOutcomes measure: Fractional Shortening (FS), secondaryOutcomes measure: Early Diastolic Velocity/Atrial Diastolic Velocity (E/A), secondaryOutcomes measure: Interventricular Septum Thickness in Diastolic (IVSTd), eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False